Sympathetic neural activity in hypertension and related diseases
- PMID: 20651696
- DOI: 10.1038/ajh.2010.154
Sympathetic neural activity in hypertension and related diseases
Abstract
Background: Several hemodynamic variables, such as blood pressure, vascular resistance, cardiac output, and heart rate, are regulated, among others, by sympathetic cardiovascular influences. This has led many years ago investigators to advance the hypothesis that alterations in the sympathetic modulation of the cardiovascular system may occur in hypertension and related disease.
Methods: The role of the sympathetic nervous system as promoter and amplifier of the hypertensive state has been examined in a consistent number of studies carried out by making use of sophisticated and sensitive approaches to evaluate adrenergic function, such as the norepinephrine spillover technique and the recording of efferent postganglionic muscle sympathetic-nerve traffic.
Results: The results of the above-mentioned investigations support the concept that adrenergic activation characterizes essential hypertension, correlating with the clinical severity of the disease. Furthermore, sympathetic cardiovascular influences may favor the hypertensive disease progression, by concurring with other hemodynamic and nonhemodynamic factors at the development of target organ damage. Finally, an adrenergic overdrive of pronounced degree also characterizes hypertension-related cardiovascular and metabolic disease. In several of these clinical conditions, the adrenergic overdrive plays a role in the disease's physiopathology and prognosis.
Conclusions: The data reviewed in this article provide evidence that sympathetic activation represents a hallmark of the essential hypertensive state. They further show that adrenergic neural factors may participate at the development and progression of the hypertensive state and its complications. This represents the rationale for the use of antihypertensive and, in more in general, cardiovascular drugs capable to exert sympatho-inhibitory effects.
Similar articles
-
[Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension].Ann Ital Med Int. 1997 Oct-Dec;12(4):217-22. Ann Ital Med Int. 1997. PMID: 9773576 Review. Italian.
-
Sympathetic activity in essential hypertension.N Engl J Med. 1973 Mar 22;288(12):627-9. doi: 10.1056/NEJM197303222881209. N Engl J Med. 1973. PMID: 4405674 No abstract available.
-
High blood pressure management: potential benefits of I1 agents.J Hypertens Suppl. 1998 Aug;16(3):S19-24. J Hypertens Suppl. 1998. PMID: 9747906 Review.
-
The role of sympathetic activation in cardiovascular disease.Postgrad Med. 2003 Dec;114(6 Suppl Role):4-10. doi: 10.3810/pgm.12.2003.suppl33.198. Postgrad Med. 2003. PMID: 19667664
-
[The role of the sympathetic nervous system in essential arterial hypertension and organ damage].Ann Ital Med Int. 1995 Oct;10 Suppl:115S-120S. Ann Ital Med Int. 1995. PMID: 8562257 Review. Italian.
Cited by
-
Effect of Low Dose Atorvastatin Therapy on Baroreflex Sensitivity in Hypertensives.High Blood Press Cardiovasc Prev. 2016 Jun;23(2):133-40. doi: 10.1007/s40292-016-0154-3. Epub 2016 May 9. High Blood Press Cardiovasc Prev. 2016. PMID: 27160718
-
Hypertension in children and adolescents: epidemiology and pathogenesis.Indian J Pediatr. 2013 Mar;80 Suppl 1:S71-6. doi: 10.1007/s12098-012-0851-4. Epub 2012 Sep 2. Indian J Pediatr. 2013. PMID: 22941155 Review.
-
Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease.High Blood Press Cardiovasc Prev. 2014 Jun;21(2):89-105. doi: 10.1007/s40292-014-0056-1. Epub 2014 May 1. High Blood Press Cardiovasc Prev. 2014. PMID: 24789091 Review.
-
Renal sympathetic denervation in patients with hypertension and chronic kidney disease: does improvement in renal function follow blood pressure control?J Clin Hypertens (Greenwich). 2014 Nov;16(11):794-800. doi: 10.1111/jch.12415. Epub 2014 Oct 8. J Clin Hypertens (Greenwich). 2014. PMID: 25293878 Free PMC article.
-
Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker.J Interv Card Electrophysiol. 2018 Jan;51(1):51-59. doi: 10.1007/s10840-017-0302-2. Epub 2017 Dec 20. J Interv Card Electrophysiol. 2018. PMID: 29264729 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical